苯那普利、芦沙坦治疗自发性高血压大鼠对肾功能及对碱性成纤维细胞生长因子、内皮素的影响

EFFECT OF BENAZEPRIL AND LOSARTAN ON THE RENAL FUNCTIONIN AND bFGF AND ET OF FIBROBLAST GROWTH FACTOR IN SHR

为与血管紧张素转换酶抑制剂（ＡＣＥＩ）苯那普利比较，研究新一代降压药血管紧张素Ⅱ受体拮抗剂芦沙坦对自发性高血压大鼠（ＳＨＲ）肾功能的影响，以及两药减轻 ＳＨＲ肾损害可能的机制，设立苯那普利治疗组、芦沙坦治疗组、未治疗组及正常血压对照组，治疗３个月后，检测肾功能、肾组织病理改变，血浆及肾组织内皮素（ＥＴ）水平和肾组织中碱性成纤维细胞生长因子（ｂＦＧＦ）的表达。结果显示，芦沙坦降压、延缓ＳＨＲ尿白蛋白排泄率与苯那普利比较差异无显著性意义，两治疗组肾组织病理损害轻，芦沙坦组血浆、肾组织中ＥＴ及苯那普利组肾组织中ＥＴ均明显降低，两组肾组织中ｂＦＧＦ的表达均减弱。结果表明，芦沙坦能延缓ＳＨＲ肾损害，苯那普利和芦沙坦减轻ＳＨＲ肾损害与其降低ＥＴ、抑制ｂＦＧＦ表达可能有关。

Compared with ACEI Benazepril, we investigated the effect of angiotension Ⅱ antagonist Losartan on the renal damage in SHR and the protective mechanism of ACEI Benazepril as well as angiotension Ⅱ antago- nist Losartan. SHR at 13 months of age were divided randomly into control group(n = 12), benazepril treated group(n=12 ) and losartan treated group (n = 12 ). Three months after treatment, renal function, pathological changes, ET level in plasma and kidney as well as bFGF expression in renal tissue were measured. After treatment for three months, the BP and UAE in Benazepril and Lorsatan groups reduced significantly and pathological chan- ges in these two groups were milder as well, with no significant difference in potency. Renal ET in Benazepril and ET in plasma and renal tissue in Losartan dereased significantly. bFGF expression in kidney in both groups was reduced. Conclusion: Both Benazepril and Losartan was able to decrease the renal lesion in SHR. It is suggested that the protective effect of Benazepril and Losartan on renal damage might be associated with the reduction of ET and inhibition of bFGF expression.